Alnylam Pharmaceuticals (ALNY) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 30.1% versus a loss of 67.0%. Over five years, JAZZ leads with a +85.6% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $14.78 billion), about 1.3 times the size.
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.6x vs 14.5x for Alnylam Pharmaceuticals). Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | JAZZ |
|---|---|---|
| Share price | $143.82 | $230.26 |
| Market cap | $19.26B | $14.78B |
| 1-day change | -2.71% | -2.62% |
| YTD return | -63.83% | +35.45% |
| 1-year return | -67.04% | +30.14% |
| 5-year return | -23.72% | +85.56% |
| P/E ratio (TTM) | 7.26 | 68.12 |
| Forward P/E | 14.51 | 8.61 |
| EPS (TTM) | $19.80 | $3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $4.27B |
| Revenue growth (YoY) | +65.19% | +4.88% |
| Net income (latest FY) | $313.75M | $-356.15M |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | -10.08% |
| Net margin | 8.45% | -8.35% |
| 52-week high | $479.79 | $266.38 |
| 52-week low | $143.40 | $156.95 |
| Distance from 52-week high | -70.02% | -13.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +101.10% | +29.20% |
| Average volume | 2.09M | 905.07K |
| Shares outstanding | 133.94M | 64.19M |
| Employees | 2,500 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed ALNY by 97.2 percentage points over the past year.
- Jazz Pharmaceuticals trades at a higher earnings multiple (68.1x vs 7.3x trailing P/E).
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +4.88%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
ALNY vs JAZZ FAQ
Which is bigger, Alnylam Pharmaceuticals or Jazz Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $14.78B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, ALNY or JAZZ?
JAZZ returned +30.14% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or JAZZ?
ALNY has the lower trailing P/E at 7.3, versus 68.1 for JAZZ. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.